| Literature DB >> 32316398 |
Bwalya A Witika1, Vincent J Smith2, Roderick B Walker1.
Abstract
<span class="Chemical">Lamivudine (3TC) and <span class="Chemical">zidovudine (AZT) are antiviral agents used to manage <span class="Disease">HIV/AIDS infection. The compounds require frequent dosing, exhibit unpredictable bioavailability and a side effect profile that includes hepato- and <span class="Disease">haema-toxicity. A novel pseudo one-solvent bottom-up approach and Design of Experiments using <span class="Chemical">sodium dodecyl sulphate (SDS) and α-tocopheryl polyethylene glycol succinate 1000 (<span class="Chemical">TPGS 1000) to electrosterically stablize the nano co-crystals was used to develop, produce and optimize 3TC and AZT nano co-crystals. Equimolar solutions of 3TC in surfactant dissolved in de-ionised <span class="Chemical">water and AZT in <span class="Chemical">methanol were rapidly injected into a vessel and sonicated at 4 °C. The resultant suspensions were characterized using a Zetasizer and the particle size, polydispersity index and Zeta potential determined. Optimization of the nanosuspensions was conducted using a Central Composite Design to produce nano co-crystals with specific identified and desirable Critical Quality Attributes including particle size (PS) < 1000 nm, polydispersity index (PDI) < 0.500 and Zeta potential (ZP) < -30mV. Further characterization was undertaken using Fourier Transform infrared spectroscopy, energy dispersive X-ray spectroscopy, differential scanning calorimetry, powder X-ray diffraction and transmission electron microscopy. In vitro <span class="Disease">cytotoxicity studies revealed that the optimized nano co-crystals reduced the <span class="Disease">toxicity of AZT and 3TC to <span class="CellLine">HeLa cells.Entities:
Keywords: HIV/AIDS; Quality by Design; crystal engineering; design of experiments; lamivudine; nano co-crystals; sonochemistry; zidovudine
Year: 2020 PMID: 32316398 PMCID: PMC7238087 DOI: 10.3390/pharmaceutics12040367
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Summary of CCD experiments for nano co-crystals (NCC) optimization.
| Std. Run | Form. Code | SDS % w/v | TPGS 1000 % w/v |
|---|---|---|---|
| 4 | 1 | 1.00 | 2.00 |
| 11 | 2 | 0.50 | 1.50 |
| 5 | 3 | 0.00 | 1.50 |
| 2 | 4 | 1.00 | 1.00 |
| 7 | 5 | 0.50 | 0.79 |
| 8 | 6 | 0.50 | 2.21 |
| 13 | 7 | 0.50 | 1.50 |
| 6 | 8 | 1.21 | 1.50 |
| 1 | 9 | 0.00 | 1.00 |
| 3 | 10 | 0.00 | 2.00 |
| 9 | 11 | 0.50 | 1.50 |
| 10 | 12 | 0.50 | 1.50 |
| 12 | 13 | 0.50 | 1.50 |
Sodium dodecyl sulphate (SDS), α-tocopheryl polyethylene glycol succinate (TPGS 1000).
Summary of optimized formulation conditions for the manufacture of optimized nano co-crystal (OPT-NCC).
| Formulation Variable | Optimized Condition |
|---|---|
|
| 0.90% w/v |
|
| 1.40% w/v |
Summary of variables used and responses for NCC produced using CCD.
| Summary of CCD Experiments for Optimisation | Responses for NCC Produced Using CCD | |||||
|---|---|---|---|---|---|---|
| Std. Run | Form. Code | SDS | TPGS | PS | PDI | ZP |
| 4 | 1 | 1.00 | 2.00 | 451.9 ± 43.1 | 0.689 ± 0.003 | −45.0 ± 3.9 |
| 11 | 2 | 0.50 | 1.50 | 446.8 ± 52.8 | 0.478 ± 0.034 | −27.7 ± 1.2 |
| 5 | 3 | 0.00 | 1.50 | 705.6 ± 92.3 | 0.474 ± 0.092 | −22.3 ± 0.9 |
| 2 | 4 | 1.00 | 1.00 | 475.9 ± 22.3 | 0.506 ± 0.033 | −30.5 ± 2.6 |
| 7 | 5 | 0.50 | 0.79 | 630.1 ± 73.2 | 0.414 ± 0.045 | −27.1 ± 1.4 |
| 8 | 6 | 0.50 | 2.21 | 304.1 ± 38.6 | 0.498 ± 0.087 | −21.9 ± 2.3 |
| 13 | 7 | 0.50 | 1.50 | 436.4 ± 67.1 | 0.471 ± 0.011 | −25.9 ± 3.1 |
| 6 | 8 | 1.21 | 1.50 | 404.9 ± 73.6 | 0.462 ± 0.038 | −37.0 ± 0.3 |
| 1 | 9 | 0.00 | 1.00 | 859.4 ± 101.2 | 0.448 ± 0.088 | −13.3 ± 3.7 |
| 3 | 10 | 0.00 | 2.00 | 656.9 ± 77.2 | 0.284 ± 0.018 | −13.5 ± 2.2 |
| 9 | 11 | 0.50 | 1.50 | 424.9 ± 21.7 | 0.432 ± 0.028 | −26.2 ± 1.6 |
| 10 | 12 | 0.50 | 1.50 | 423.7 ± 13.2 | 0.449 ± 0.049 | −25.3 ± 0.7 |
| 12 | 13 | 0.50 | 1.50 | 430.7 ± 52.1 | 0.466 ± 0.009 | −24.8 ± 2.7 |
Shaded cells reflect results that have met the critical quality attributes (CQA) [25]. PS, particle size; PDI, polydispersity index; ZP, Zeta potential.
ANOVA data for response surface quadratic model for PS.
| Source | Sum of Squares | df | Mean Square | F-Value | |
|---|---|---|---|---|---|
| Model | 2.71 | 5 | 54,111.2 | 26.82 |
|
| A-SDS Conc. | 1.68 | 1 | 1.679 | 83.23 |
|
| B-TGPS Conc. | 59,087.81 | 1 | 59,087.8 | 29.29 |
|
| AB | 7965.56 | 1 | 7965.56 | 3.95 |
|
| A2 | 73,941.57 | 1 | 73,941.6 | 36.65 |
|
| B2 | 6594.86 | 1 | 6594.86 | 3.27 | 0.1135 |
| Residual | 14,121.22 | 7 | 2017.32 | ||
| Lack of Fit | 13,763.08 | 3 | 4587.69 | 51.24 |
|
| Pure Error | 358.14 | 4 | 89.54 | ||
| Corr. Total | 2.85 | 12 |
Significant factors are reported in red.
Figure 13D response surface plot depicting the impact of SDS and TPGS 1000 concentration on particle size of the NCC.
ANOVA data for response surface linear model for PDI.
| Source | Sum of Squares | df | Mean Square | F-Value | |
|---|---|---|---|---|---|
| Model | 0.061 | 3 | 0.02 | 6.37 |
|
| A-SDS Concentration | 0.029 | 1 | 0.029 | 8.99 |
|
| B-TGPS Concentration | 2.37 × 10−3 | 1 | 2.37 × 10−3 | 0.74 | 0.412 |
| AB | 0.03 | 1 | 0.03 | 9.39 | 0.0135 |
| Residual | 0.029 | 9 | 3.21 × 10−3 | ||
| Lack of Fit | 0.027 | 5 | 5.496 × 10−3 | 15.9 |
|
| Pure Error | 1.38 × 10−3 | 4 | 3.457 × 10−3 | ||
| Corr. Total | 0.09 | 12 |
Significant factors are reported in red.
Figure 23D response surface plot depicting the impact of SDS and TPGS 1000 concentration on the PDI of the NCC.
ANOVA data for response surface linear model for ZP.
| Source | Sum of Squares | df | Mean Square | F-Value | |
|---|---|---|---|---|---|
| Model | 666.17 | 2 | 333.08 | 17.56 |
|
| A-SDS Concentration | 659.42 | 1 | 659.42 | 34.76 |
|
| B-TGPS Concentration | 6.75 | 1 | 6.75 | 0.36 | 0.5642 |
| Residual | 189.72 | 10 | 18.97 | ||
| Lack of Fit | 184.85 | 6 | 30.81 | 25.32 |
|
| Pure Error | 4.87 | 4 | 1.22 | ||
| Corr. Total | 855.89 | 12 |
Significant factors are reported in red.
Figure 33D response surface plot depicting the impact of SDS and TPGS 1000 concentration on ZP of the NCC.
Formulation variables and associated responses.
| Formulation Variables | Formulation Responses | Desirability | |||
|---|---|---|---|---|---|
| SDS | TPGS | PS | PDI | ZP | |
| 0.90 | 1.40 | 393.08 | 0.499 | −33.47 | 1.000 |
Summary of results for the NCC produced using optimum formulation parameters.
| Response | Predicted Value | Experimental Value | % Predicted Error |
|---|---|---|---|
|
| 393.08 | 332.9 ± 42.85 | 18.08 |
|
| 0.499 | 0.474 ± 0.040 | 5.27 |
|
| −33.47 | −34.6 ± 5.56 | 3.27 |
Figure 4DSC thermograms depicting the melting endotherm for the uncoated (black) and OPT-NCC (orange).
Summary of elemental analysis for the physical mixture, NCC-OPT and co-crystal.
| Element | OPT-NCC | Uncoated NCC |
|---|---|---|
| Atomic % | Atomic % | |
|
| 56.97 ± 2.18 | 49.67 ± 1.21 |
|
| 13.99 ± 0.94 | 20.81 ± 0.94 |
|
| 25.87 ± 1.22 | 28.53 ± 1.02 |
|
| 0.26 ± 0.13 | - |
|
| 2.97 ± 0.34 | 1.00 ± 0.03 |
Figure 5Elemental analysis of uncoated (black) and OPT-NCC (orange).
Figure 6FTIR absorption spectra of the uncoated NCC (black) and the OPT-NCC (orange).
Figure 7PXRD diffractograms for the uncoated (black) and OPT-NCC (orange).
Figure 8TEM micrograph of prismatic OPT-NCC.
Summary of in vitro cytotoxicity results.
| Compound | Cell Viability % | SD |
|---|---|---|
| OPT-NCC | 76.9 | 5.0 |
| Physical Mixture | 52.6 | 5.1 |
| AZT | 49.6 | 6.2 |
| 3TC | 62.3 | 4.7 |
Figure 9Cytotoxicity of NCC, individual API and physical mixture of active pharmaceutical ingredient (API).